Clinical Study Of Domestic Imatinib In Newly Diagnosed Patients With Chronic Myeloid Leukemia

Objective Analysis of short term efficacy and side effects of imatinib in the treatment of newly diagnosed chronic myeloid leukemia.Method A retrospective analysis of our hospital from 2014.1 to 2016.07 were chronic myeloid leukemia in 44 cases,all patients were treated with bone marrow cell morphology and cytogenetic diagnosis,with different drugs into domestic imatinib and imatinib mesylate(Greve)group,domestic imatinib group application of imatinib for treatment with imatinib mesylate(Greve)should adopt imatinib mesylate therapy(Greve).To observe the curative effect and treatment related adverse reactions.Results 1.Lattice Nicole group does not consider stopping patients,all CML patients were CHR at three months;9 cases(40.9%)of CML patients at three months reached CCy R,accounting for 40.9%;15 six months patients reached CCy R,accounting for 68.2%;12months,16 patients reached CCy R,accounting for 76.2%;5 patients reached MMR,accounting for 23.8%;1 cases of CMR,accounting for 4.8%.six months,the median reached CCy R..To complete the follow-up,taking 9 of the patients in case Nicole patients followed up for 1.5 years,the 9 patients in 12 months have reached CCy R,CCy R still maintained the end of the follow-up,including 2(20.2%)patients has reached MMR,1 patients has reached CMR(11.1%).Lattice Nicole withdrawal was removed in 21 evaluable patients,cytogenetic response patients,16 patients with CML at 3 months,BCR-ABL?10%(accounting for 76.2%),14 CML patients reached CCy R at 12 months,accounting for 90.5%,compared with 3 months of the 5BCR-ABL>10% patients,2 CML patients reached CCy R at 12 months,which accounted for40%,the comparison was statistically significant(P < 0.05).There were 13 patients in 6months when BCR-ABL ?l%,accounting for 61.9%,of which 9 patients at 12 months was CCy R,accounting for 69.2% of the 13 patients.While in 6 months 8 cases of BCR-ABL>l%,4 cases reached CCy R at the age of 12 months,accounting for 50%,the difference between the two groups was obvious.Through the Sokal score,a total of 16 low-risk patients,of which11 people at the age of 12 months of CCy R,accounting for more than 68.8%,there were 4patients in the middle of the crisis,at the end of the month of all CCy R,accounting for 100%.There was no significant difference between the two groups.The EFS rate of 22 CML patients was 86.4%.2.Take Nicole lattice in 22 CML patients,a total of 9 patients had neutropenia,accounted for 40.9%,including three of the total of 1 cases,accounting for 11.1%;a total of 4 patients had decreased PLT,accounting for 18.2,1 cases of grade 3;a total of 7 cases anemia,accounting for 31.8% of all 1/2.1/2 grade adverse reactions in normal circumstances,can improve their own.Patients with primary CML caused by taking drugs Nicole lattice nonhematologic adverse reactions to 1/2 level,most of the patients have tolerated,common adverse symptoms see a slight swelling in 12 cases,accounting for 54.5%;10 cases of nausea and vomiting,accounted for 45.5%;5 cases of muscle soreness,accounting for 22.7%;2cases of allergic rash,accounting for 9.5%;4 cases of joint pain,dizziness and headache,accounting for 18.2%;3 cases,accounting for 13.6%;3 cases of diarrhea,accounted for13.6%;1 cases were weak,accounting for 4.5%.There were 1 cases of adverse reactions,AKP increased,accounting for the proportion of low blood glucose in the treatment of 2 cases,accounting for the proportion of,bilirubin,elevated GGT,GPT increased in each of the 1cases,accounting for more than 4.5%.3 patients had grade 3 adverse events,including rash,hypokalemia,and hyperphosphatemia in each of the 1 patients(each accounting for 4.5%).Among them,the rash patients withdrew from the study.3.The average concentration of the 22 patients with chronic myelogenous leukemia patients treated 1 years Nicole lattice lattice Nicole and its metabolites were 1100.31±425.89(525.28~1934.98)ng/ml,without considering the withdrawal of patients were 1185.01 ±417.89(590.68~1934.99)ng/ml.22 cases of CML patients,with the increase of time,CCy R,MMR rate also increased.The analysis can assess the efficacy of the 21 patients with lattice Nicole trough plasma concentration,12 months,5 patients average trough plasma concentration of MMR was 1403.31±268.86 ng/ml,MMR did not reach the rest of the 16 patients was 1005.20±442.01 ng/ml,the former was slightly higher than that of the latter,the results of no significant difference.At the same time,the drug plasma concentration of 12 months of CCy R and reach CCy R,respectively,was 1194.04±444.01 ng/ml? 836.68±308.29 ng/ml,the former was higher than the latter,but there was no significant difference between the two groups.The average blood concentration below 1000 ng/ml patients,12 months amounted to a total of 11 cases of CCy R(91.7%),higher than 1000 in patients with ng/ml,CCy R,a total of 8 cases(80%),there was no significant difference compared with CCy R blood concentration has no obvious correlation.Lattice Nicole steady state plasma trough concentration and age(years),weight(Kg)and the surface area of M2 had no significant relationship(P>0.05).Conclusion The clinical efficacy of generic drugs and Nicole lattice generated by Gleevec also has similar safety,both bioequivalent.There were some differences between the clinical efficacy and the individual of the patients.In general,lattice Nicole lower cost alternative for CML patients with Gleevec to provide a more effective way for the treatment,reliable,economic and safe.